MPA increases Idarubicin-induced apoptosis in Chronic Lymphatic Leukaemia cells via Caspase-3

Journal of Cellular Biochemistry

Volumn 89, Issue 4, 2003, Pages 747-754

  Florio, Salvatore ^a   Crispino, Luca ^a   Ciarcia, Roberto ^a   Vacca, Giovanni ^a   Pagnini, Ugo ^a   De Matteis, Andrea ^c   Pacilio, Carmen ^c   D'Andrilli, Giuseppina ^b   Kumar, Christine ^b   Giordano, Antonio ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Temple University   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Caspase 3; Idarubicin; Medroxyprogesterone acetate

Indexed keywords

CASPASE 3; IDARUBICIN; MEDROXYPROGESTERONE ACETATE; PROPIDIUM IODIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOG; ENZYME ACTIVATION; FLUOROMETRY; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASES; DOGS; DRUG SYNERGISM; ENZYME INHIBITORS; FLUOROMETRY; IDARUBICIN; ISOENZYMES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MEDROXYPROGESTERONE 17-ACETATE; NUCLEOSOMES; PROPIDIUM; TUMOR CELLS, CULTURED;

EID: 0037974274     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10556     Document Type: Article

References (37)

1. Abe M, Yamashita J, Ogawa M. 2000. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorilation. Cancer 88:2000-2009.
2. Anderstrom C. 1994. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer. Cancer Chemother Pharmacol 35(Suppl):S97-S100.
3. Bass DA, Dechatelet LR, McCall CE. 1978. Independent stimulation of motility and the oxidative metabolic burst of human polymorphonuclear leukocytes. J Immunol 121:172-178.
4. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. 1996. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res 56:1851-1854.
5. Blossey HC, Wander WE, Koebberling J, Nagel GA. 1984. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54:1208-1215.
6. Cavalli F, Goldhirsch A, Jungi F, Marta G, Mermillod B, Alberto F. 1984. Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2(5):414-419.
7. Dalton WS. 1993. Drug resistance: Modulation in the laboratory and clinic. Semin Oncol 20:64-69.
8. Fleming GF, Amato JM, Agresti M, Safa AR. 1992. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol 29:445-449.
9. Fulda S, Susin SA, Kroemer G, Debatin KM. 1998. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 58:4453-4460.
10. Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo M, Pineiro A, Naval J. 1997. Doxorubicin-induced apoptosis in human T-cell leukaemia is mediated by caspase-3 activation in Fas-independent way. FEBS Lett 417:360-364.
11. Haberl I, Swatonek H, Schaufler K, Uleperger E, Wenzl E, Theyer G, Hamilton G, Thalhammer T. 1998. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. Int J Oncol 12:1137-1142.
12. Haldar S, Chintapalli J, Croce C. 1996. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255.
13. Hupperets PS, Wils J, Volovics L, Schuten L, Fickers M, Bron H, Schouten HC, Jager J, Smeets J, De Jong J. 1993. Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracile (CAF) with or without medroxyprogesterone acetate for node positive breast cancer patients. Ann Oncol 4:295-301.
14. Kantrowitz NE, Bristow MR. 1984. Cardiotoxicity of antitumour agents. Prog Cardiovasc Dis 27:195-200.
15. Kave SB. 1993. P-glycoprotein (P-gp) and drug resistance-time for reappraisals. Br J Cancer 67:703-707.
16. Keane MM, Ettemberg SA, Nau MM, Russel EK, Lipkowitz S. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cancer lines. Cancer Res 58: 734-741.
17. Liu FT, Kelsey SM, Newland AC, Jia L. 2001. Generationof reactive oxygen species is not involved in idarubicin-induced apoptosis in human leukaemic cells. Br J Haematol 115:817-825.
18. Liu FT, Kelsey SM, Newland AC, Jia L. 2002. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leuhaemic cells. Br J Haematol 117:333-342.
19. Los M, Herr I, Friesen C, Fulda S, Schulze-osthoff K, Debatin KM. 1997. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activationof caspases (ICE/Ced-3 proteases). Blood 90: 3118-3129.
20. Matteucci C, Grelli S, DeSmaele E, Fontana C, Mastino A. 1999. Identification of nuclei from apoptotic, necrotic and viable lymphoid cells by using multiparameter glow cytometry. Cytometry 35:145-153.
21. Merlin JL, Guerci A, Marchal S, Massoum N, Ramacci C, Humbert JC, Tsuruo T, Guerci O. 1994. Comparative evaluation of S9788, verapamil and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84:262-269.
22. Nicholson DV. 1996. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat Biotechnol 14:297-301.
23. Ory K, Lebeau J, Levalois C, Bishay K, Fouchet P, Allemand I, Therwath A, Chevillard S. 2001. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat 68:187-198.
24. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parillo JE, Young RC. 1987. Verapamil and adryamicin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:5002-5006.
25. Pacilio C, Florio S, Pagnini U, Crispino A, Claudio PP, Pacilio G, Pagnini G. 1998. Modification of membrane fluidity and depolarization by some anthracyclines on different cell lines. Interference by Medroxyprogesterone acetate and Verapamil. Anticancer Res 18:4027-4034.
26. Pagnini U, Pacilio C, Florio S, Crispino A, Claudio PP, Giordano A, Pagnini G. 2000. Medroxyprogesterone acetate increases anthracyclines uptake in chronic lymphatic leucemia cells: Role of nitric oxide and lipid peroxidation. Anticancer Res 20:33-42.
27. Reichle A, Diddens H, Altmayr F, Rastetter J, Abdreesen R. 1994. Chemomodulation of drug involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type. Cancer Chemother Pharmacol 34:307-316.
28. Saltiel E, McGuire W. 1983. Doxorubicin (adriamycin) cardiomyopathy. West J Med 139:332-341.
29. Schmitt CA, Lowe SW. 1999. Apoptosis and therapy. J Pathol 187:127-137.
30. Sikie BI. 1993. Modulation of multidrug resistance: At the threshold. J Clin Oncol 11:1629-1635.
31. Sonnevel P, Durie BG, Lokhurst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg G, Noore K. 1992. Modulation of multi-drug resistant multiple myeloma by ciclosporin. Lancet 340:255-259.
32. Steller H. 1995. Mechanism and genes of cellular suicide. Science 267:1445-1449.
33. Wang L, Yang CPH, Horwitz SB, Trail PA, Casazza AM. 1994. Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. Cancer Chemother Pharmacol 34:96-102.
34. Wesselborg S, Engels IH, Rossmann E, Los M, Osthoff K. 1999. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93:3053-3063.
35. Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T, Ogawa O. 2001. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 19:19-24.
36. Young RCN, Ozols RF, Myers CE. 1981. The anthracycline antineoplastic drugs. Engl J Med 305:139-153.
37. Yusa K, Tsuruo T. 1989. Reversal mechanism of multidrug-resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49:5003-5006.